atrial fibrillation, paroxysmal, persistent, StudyID: ATHENA 2009
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2009 Feb 12;360(7):668-78 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal, persistent, StudyID: ATHENA 2009 The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To reduce at 21 months cardiovascular deaths (2.7% dronedarone VS 3.9% placebo) and hospitalizations (26.9% dronedarone VS 33.4% placebo). No significant difference in overall mortality.
Circulation. 2009 Sep 29;120(13):1174-80 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, persistent, StudyID: ATHENA 2009, subordinated publication The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To reduce annual risk of stroke (all types): 1.2% dronedarone VS 1.8% placebo